"Compositions Targeting Pacs1 And Methods Of Use Thereof" in Patent Application Approval Process (USPTO 20230416740).

A patent application has been filed for compositions that target Pacs1 and their use in treating lymphoproliferative diseases (LPDs). LPDs are caused by immune system defects, resulting in excessive lymphocyte production. The invention aims to modulate Pacs1 to block lymphoproliferation associated with LPDs. The methods involve administering compositions that can decrease Pacs1 gene expression, protein expression, or activity, and kits containing these compositions are provided for treating LPDs and lymphoid malignancies. The invention offers a method and composition for attenuating or preventing lymphoproliferation in subjects with LPDs or at risk of developing these conditions, which can be used in combination with other therapies. [Extracted from the article]